Lu-Meng Zhou1,2, Ling-Ling Yuan3, Yan Gao1, Xu-Sheng Liu1, Qin Dai4, Jian-Wei Yang2, Zhi-Jun Pei5,6,7,8. 1. Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China. 2. Postgraduate Training Basement of Jinzhou Medical University, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 3. Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 4. Department of Eye center, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 5. Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China. pzjun1980@yeah.net. 6. Postgraduate Training Basement of Jinzhou Medical University, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. pzjun1980@yeah.net. 7. Hubei Key Laboratory of WudangLocal Chinese Medicine Research, Shiyan, Hubei, China. pzjun1980@yeah.net. 8. Hubei Key Laboratory of Embryonic Stem Cell Research, Shiyan, Hubei, China. pzjun1980@yeah.net.
Abstract
PURPOSE: This study investigated the correlation of nucleophosmin 1 (NPM1) expression with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computerised tomography scan (PET/CT)-related parameters and compared the diagnostic value of NPM1 with that of the positive biomarker TTF1 in lung adenocarcinoma patients. METHODS: Forty-six lung adenocarcinoma patients who underwent 18F-FDG PET/CT before pulmonary surgery were retrospectively analysed. Metabolic parameters including SUVmax, SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were calculated from 18F-FDG PET imaging data. The expression levels of NPM1 and TTF1 were assessed using The Cancer Genome Atlas (TCGA) database and immunohistochemistry of tumour tissues and adjacent normal lung tissues. We examined the association between the frequency of NPM1 and TTF1 expression and the metabolic parameters. RESULTS: Lung adenocarcinoma samples expressed higher levels of NPM1 than adjacent normal lung epithelial tissues. NPM1 showed higher specificity and sensitivity for lung adenocarcinoma compared with TTF1 (p < 0.001). SUVmax, SUVmean and TLG correlated with NPM1 expression (p < 0.001). MTV was inversely correlated with TTF1 (p < 0.01). SUVmax was the primary predictor of NPM1 expression by lung adenocarcinoma (p < 0.01). A cutoff value for the SUVmax of 3.93 allowed 90.9% sensitivity and 84.6% specificity for predicting NPM1 overexpression in lung adenocarcinoma. CONCLUSION: NPM1 overexpression correlated with 18F-FDG PET/CT metabolic parameters and improved diagnostic accuracy in lung adenocarcinoma. SUVmax on 18F-FDG PET/CT may estimate NPM1 expression for targeted therapy of lung adenocarcinoma.
PURPOSE: This study investigated the correlation of nucleophosmin 1 (NPM1) expression with 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computerised tomography scan (PET/CT)-related parameters and compared the diagnostic value of NPM1 with that of the positive biomarker TTF1 in lung adenocarcinoma patients. METHODS: Forty-six lung adenocarcinoma patients who underwent 18F-FDG PET/CT before pulmonary surgery were retrospectively analysed. Metabolic parameters including SUVmax, SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis (TLG) were calculated from 18F-FDG PET imaging data. The expression levels of NPM1 and TTF1 were assessed using The Cancer Genome Atlas (TCGA) database and immunohistochemistry of tumour tissues and adjacent normal lung tissues. We examined the association between the frequency of NPM1 and TTF1 expression and the metabolic parameters. RESULTS: Lung adenocarcinoma samples expressed higher levels of NPM1 than adjacent normal lung epithelial tissues. NPM1 showed higher specificity and sensitivity for lung adenocarcinoma compared with TTF1 (p < 0.001). SUVmax, SUVmean and TLG correlated with NPM1 expression (p < 0.001). MTV was inversely correlated with TTF1 (p < 0.01). SUVmax was the primary predictor of NPM1 expression by lung adenocarcinoma (p < 0.01). A cutoff value for the SUVmax of 3.93 allowed 90.9% sensitivity and 84.6% specificity for predicting NPM1 overexpression in lung adenocarcinoma. CONCLUSION: NPM1 overexpression correlated with 18F-FDG PET/CT metabolic parameters and improved diagnostic accuracy in lung adenocarcinoma. SUVmax on 18F-FDG PET/CT may estimate NPM1 expression for targeted therapy of lung adenocarcinoma.
Authors: Jeong-Yeop Song; Yun Nah Lee; Young Seok Kim; Sang Gyune Kim; Soo Ji Jin; Jung Mi Park; Gyu Seong Choi; Jun Chul Chung; Min Hee Lee; Youn Hee Cho; Moon Han Choi; Dong Choon Kim; Hyun Jong Choi; Jong Ho Moon; Se Hwan Lee; Seung Won Jeong; Jae Young Jang; Hong Soo Kim; Boo Sung Kim Journal: Nucl Med Commun Date: 2015-04 Impact factor: 1.690
Authors: Viswam S Nair; Olivier Gevaert; Guido Davidzon; Sandy Napel; Edward E Graves; Chuong D Hoang; Joseph B Shrager; Andrew Quon; Daniel L Rubin; Sylvia K Plevritis Journal: Cancer Res Date: 2012-06-18 Impact factor: 12.701
Authors: Hubert Vesselle; Alexander Salskov; Eric Turcotte; Linda Wiens; Rodney Schmidt; C Diana Jordan; Eric Vallières; Douglas E Wood Journal: J Thorac Oncol Date: 2008-09 Impact factor: 15.609
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702